Intellia Therapeutics has named Perry Karsen the chairman of its board of directors.
Until January, Karsen was CEO of Celgene Cellular Therapeutics. Previously he served as COO and executive VP at Celgene, president and CEO of Pearl Therapeutics, and has held executive positions at Human Genome Sciences, Bristol-Myers Squibb, Genentech, and Abbott Laboratories.
Karsen also serves on the board OncoMed Pharmaceuticals, Voyager Therapeutics, Jounce Therapeutics, and Pliant Therapeutics. He holds an undergraduate degree in biology from the University of Illinois, Urbana-Champaign, a master's degree in biology education from Duke University, and a Master of Management degree from Northwestern University's Kellogg Graduate School of Management.